Outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
-
"At 24–72 h after TCZ administration, 58 patients (58%) showed a rapid improvement of clinical and respiratory condition, 37 (37%) stabilized compared to the rapidly declining pre-TCZ condition, and 5 (5%) worsened (of whom 4 died)"
-
BCRSS scores decreased on average, but had a similar range of values. See figure in child node "Figure 2. Changes in Brescia COVID-19 Respiratory Severity Scale (BCRSS) among 100 severe COVID-19 patients in Brescia, Italy during 10-day follow-up after Tocilizumab (TCZ) infusion"
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
Outcomes among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Patient characteristics among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Laboratory findings among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Methods for tracking outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
Discussion from "Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy"